Is Vutiglabridin Approved? Current Status and PON1 Timeline (2026)
No. Vutiglabridin is still a Phase 2 asset. It is an interesting metabolic program, but it is not close to approval.
Current stage
Phase 2
Approval read
Not approved.
Likely window
2028 or later if the program keeps progressing.
Next step
Turn the metabolic-science story into clearer clinical and commercial relevance.
Direct answer
No. Vutiglabridin is still a Phase 2 asset. It is an interesting metabolic program, but it is not close to approval.
Status facts for search and AI answers
What this Vutiglabridin (HSG4112) status page answers
Compound
Vutiglabridin (HSG4112)
Vutiglabridin (HSG4112) is tracked as a PON1 modulator program from Glaceum.
Approval read
Not approved.
No. Vutiglabridin is still a Phase 2 asset. It is an interesting metabolic program, but it is not close to approval.
Likely window
2028 or later if the program keeps progressing.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Turn the metabolic-science story into clearer clinical and commercial relevance.
This is the milestone most likely to change the page's answer.
Decision path
What does Vutiglabridin (HSG4112)'s status mean for access?
Vutiglabridin (HSG4112)'s approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- Vutiglabridin (HSG4112)
- Stage
- Phase 2
- Approval read
- Not approved.
- Window
- 2028 or later if the program keeps progressing.
Step 1
Classify availability
Phase 2 non-incretin program with a differentiated metabolic angle but limited broad-market visibility so far.
Read compound pageStep 2
Watch required milestone
Turn the metabolic-science story into clearer clinical and commercial relevance.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 2 non-incretin program with a differentiated metabolic angle but limited broad-market visibility so far.
Vutiglabridin matters because the obesity field is still looking for non-incretin approaches that do not just feel like side projects.
What needs to happen next
Turn the metabolic-science story into clearer clinical and commercial relevance.
What FormBlends is watching
- Whether the metabolic angle sharpens into a clearer obesity story
- How much clinical traction the asset actually earns
- Whether sponsor visibility improves
What could delay the timeline
- Low awareness
- A mechanism story that stays too technical
- Failure to stand out in the mid-stage crowd